Position nette de la France pour les investissements directs au 31 décembre 2005.

La position nette de la France pour les investissements directs en valeur comptable a fortement progressé en 2005 (44 %). Cette hausse reflète une augmentation deux fois plus rapide des avoirs que des engagements en investissements directs de la France.position extérieure, investissements directs, IDE.

Position nette de la France pour les investissements directs au 31 décembre 2004.

La position extérieure de la France en investissements directs à fin 2004 confirme le caractère résolument international de son économie, avec des stocks français à l’étranger et étrangers en France qui, évalués en valeur comptable, représentent respectivement 37,2 % et 27,8 % de son PIB.position extérieure, investissements directs, IDE.

Raman G band in double-wall carbon nanotubes combining p doping and high pressure

We use sulfuric acid as pressure medium to extrapolate the G-band position of the inner and outer tubes of double-wall carbon nanotubes. Keeping the G-band position of the inner and outer tubes constant, we can determine the fraction of double-wall and single-wall tubes in samples containing a mixture of the two. A-band-related electronic interwall interaction at 1560 cm−1 is observed, which is associated with the outer tube walls. This band is observed to shift with pressure at the same rate as the G band of outer tubes and is not suppressed with chemical doping. Differences in the interwall interaction is discussed for double-wall carbon nanotubes grown by the catalytic chemical-vapor method and double-wall carbon nanotubes obtained through transformation of peapods

Multicentric Castleman's disease as a cause for unclear febrile episodes in a 55-year-old HIV-infected man

Our case illustrates the difficulties involved in diagnosing multicentric Castleman's disease (MCD) in a human immunodeficiency virus-infected man with febrile episodes and malaise. In the absence of well-established treatment protocols, we have chosen a new treatment algorithm with rituximab, etoposide, and valganciclovir, which led to the remission of clinical symptoms. Yet, we advocate focused exploration for MCD in immunosuppressed patients with unclear febrile episodes, as recent advances in treatment are promisin